359 related articles for article (PubMed ID: 17131411)
21. Synchronous metastatic medullary and papillary thyroid carcinomas in a patient with germline RET mutation: case report, molecular analysis, and implications for pathogenesis.
Griffith C; Zhang S; Mukhopadhyay S
Endocr Pathol; 2010 Jun; 21(2):115-9. PubMed ID: 20369307
[TBL] [Abstract][Full Text] [Related]
22. [Pathogenesis of differentiated thyroid cancer (papillary and follicular)].
Maciel RM; Kimura ET; Cerutti JM
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):691-700. PubMed ID: 16444351
[TBL] [Abstract][Full Text] [Related]
23. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
[TBL] [Abstract][Full Text] [Related]
25. Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
Banito A; Pinto AE; Espadinha C; Marques AR; Leite V
Clin Endocrinol (Oxf); 2007 Nov; 67(5):706-11. PubMed ID: 17651453
[TBL] [Abstract][Full Text] [Related]
26. Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings.
Frau DV; Lai ML; Caria P; Dettori T; Coni P; Faa G; Morandi L; Tallini G; Vanni R
J Clin Endocrinol Metab; 2008 Jan; 93(1):177-81. PubMed ID: 17956956
[TBL] [Abstract][Full Text] [Related]
27. [Oncogenes and thyroid tumors].
Lacroix L; Soria JC; Bidart JM; Schlumberger M
Bull Cancer; 2005 Jan; 92(1):37-43. PubMed ID: 15689324
[TBL] [Abstract][Full Text] [Related]
28. RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii.
Coyne C; Nikiforov YE
Endocr Pathol; 2010 Jun; 21(2):144-7. PubMed ID: 19898969
[TBL] [Abstract][Full Text] [Related]
29. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.
Rodrigues R; Roque L; Espadinha C; Pinto A; Domingues R; Dinis J; Catarino A; Pereira T; Leite V
Oncol Rep; 2007 Oct; 18(4):917-26. PubMed ID: 17786355
[TBL] [Abstract][Full Text] [Related]
30. [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma].
Zhu XL; Zhou XY; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):270-4. PubMed ID: 16181547
[TBL] [Abstract][Full Text] [Related]
31. Molecular pathology of well-differentiated thyroid carcinomas.
Sobrinho-Simões M; Preto A; Rocha AS; Castro P; Máximo V; Fonseca E; Soares P
Virchows Arch; 2005 Nov; 447(5):787-93. PubMed ID: 16189702
[TBL] [Abstract][Full Text] [Related]
32. [Fine-needle aspiration cytology of thyroid nodules: molecular diagnostics in a routine diagnostic setting].
Eszlinger M; Neustadt M; Ruschenburg I; Neumann A; Franzius C; Adam S; Bacher K; Hach A; Hammoser R; Langvogt C; Molwitz T; Paschke R
Dtsch Med Wochenschr; 2014 Mar; 139(10):476-80. PubMed ID: 24570192
[TBL] [Abstract][Full Text] [Related]
33. Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation.
Moses W; Weng J; Khanafshar E; Duh QY; Clark OH; Kebebew E
J Surg Res; 2010 May; 160(2):179-83. PubMed ID: 19765726
[TBL] [Abstract][Full Text] [Related]
34. [Gene abnormalities in thyroid cancer].
Namba H; Yamashita S
Nihon Rinsho; 2007 Nov; 65(11):1967-72. PubMed ID: 18018556
[TBL] [Abstract][Full Text] [Related]
35. [Genetic causes of the thyroid carcinomas].
Jindrichová S; Vlcek P; Bendlová B
Cas Lek Cesk; 2004; 143(10):664-8. PubMed ID: 15584614
[TBL] [Abstract][Full Text] [Related]
36. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
Moura MM; Cavaco BM; Pinto AE; Leite V
J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
[TBL] [Abstract][Full Text] [Related]
37. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.
Ciampi R; Nikiforov YE
Endocrinology; 2007 Mar; 148(3):936-41. PubMed ID: 16946010
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance.
Acquaviva G; Visani M; Repaci A; Rhoden KJ; de Biase D; Pession A; Giovanni T
Histopathology; 2018 Jan; 72(1):6-31. PubMed ID: 29239040
[TBL] [Abstract][Full Text] [Related]
39. RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas.
de Vries MM; Celestino R; Castro P; Eloy C; Máximo V; van der Wal JE; Plukker JT; Links TP; Hofstra RM; Sobrinho-Simões M; Soares P
Histopathology; 2012 Nov; 61(5):833-43. PubMed ID: 22803838
[TBL] [Abstract][Full Text] [Related]
40. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]